Readministration of calcineurin inhibitors for ulcerative colitis;Administration additionnelle des inhibiteurs de la calcineurine pour le traitement de la colite ulcéreuse

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1315-1321

  Hiraoka, Sakiko ^a   Kato, Jun ^b   Suzuki, Hideyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcineurin inhibitors; Readministration; Ulcerative colitis

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; PREDNISOLONE; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SYMPTOM; TEACHING HOSPITAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CHILD; COLITIS, ULCERATIVE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867776990     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R210     Document Type: Article

References (30)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347: 417-29.
2. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to cortico-steroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10.
3. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6: 1112-6.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ul-cerative colitis refractory to steroid therapy. N Engl J Med 1994;330: 1841-5.
5. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporin ver-sus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
6. Van Assche G, D'Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31.
7. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. In-flamm Bowel Dis 2004;10:73-8.
8. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colecto-my during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-5.
9. Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic im-provement is important for 1-year avoidance of colectomy but not for the longterm prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol 2011;45:129-37.
10. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory col-itis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8:317-24.
11. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62.
12. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroidrefractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006;101:1048-56.
13. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008;14:7-12.
14. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589-97.
15. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J 1955;2: 1041-8.
16. Mowat C, Cole A, Windsor A, et al, IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
17. Biancone L, Michetti P, Travis S, et al., for the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008;2:63-92.
18. Kornbluth A, Sachar DB, Practice Parameters Committee of the Ameri-can College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23.
19. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a 5-year experience. Am J Gastroenterol 1999;94:1587-92.
20. Yamamoto S, Nakase H, Matsuura M, Masuda S, Inui K, Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining re-mission in patients with refractory ulcerative colitis. J Clin Gastroenterol 2011;45:526-30.
21. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I ran-domised trial. Lancet 2002;359:1541-9.
22. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-76.
23. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2011;18:212-8.
24. Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue med-ication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther 2010;31:1036-41.
25. Yamamoto S, Nakase H, Matsuura M, et al. Efficacy and safety of inflix-imab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 2010;25:886-91.
26. Takemoto K, Kuriyama M, Kato J, et al. Ratio of platelet reduction is an early predictive factor for the effectiveness of leukocytapheresis for ul-cerative colitis patients. Ther Apher Dial 2009;13:6-13.
27. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis ther-apy: a prospective cohort study. Inflamm Bowel Dis 2010;16:1905-11.
28. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009; 104:2990-5.
29. Sands BE, Sandborn WJ, Feagan B, et al. Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/mono-cyte apheresis for active ulcerative colitis. Gastroenterology 2008;135: 400-9.
30. Dittrich K, Richter M, Rascher W, Köhler H. Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A. Inflamm Bowel Dis 2008;14:1466-7.